GB201802486D0 - Methods - Google Patents

Methods

Info

Publication number
GB201802486D0
GB201802486D0 GBGB1802486.9A GB201802486A GB201802486D0 GB 201802486 D0 GB201802486 D0 GB 201802486D0 GB 201802486 A GB201802486 A GB 201802486A GB 201802486 D0 GB201802486 D0 GB 201802486D0
Authority
GB
United Kingdom
Prior art keywords
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1802486.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to GBGB1802486.9A priority Critical patent/GB201802486D0/en
Publication of GB201802486D0 publication Critical patent/GB201802486D0/en
Priority to ARP190100349A priority patent/AR114105A1/es
Priority to AU2019220407A priority patent/AU2019220407B2/en
Priority to CN201980012164.7A priority patent/CN111683965B/zh
Priority to US16/970,391 priority patent/US11524997B2/en
Priority to JP2020542852A priority patent/JP7395485B2/ja
Priority to EA202091891A priority patent/EA202091891A1/ru
Priority to PCT/EP2019/053726 priority patent/WO2019158658A1/en
Priority to BR112020015961-1A priority patent/BR112020015961A2/pt
Priority to CA3090404A priority patent/CA3090404A1/en
Priority to RU2020129443A priority patent/RU2790992C2/ru
Priority to KR1020207026431A priority patent/KR20200121833A/ko
Priority to MX2020007431A priority patent/MX2020007431A/es
Priority to SG11202005735SA priority patent/SG11202005735SA/en
Priority to EP19706471.0A priority patent/EP3752527A1/en
Priority to IL276491A priority patent/IL276491A/en
Priority to CL2020002040A priority patent/CL2020002040A1/es
Priority to CONC2020/0009731A priority patent/CO2020009731A2/es
Priority to CL2021002176A priority patent/CL2021002176A1/es
Priority to US18/062,608 priority patent/US12240896B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1802486.9A 2018-02-15 2018-02-15 Methods Ceased GB201802486D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1802486.9A GB201802486D0 (en) 2018-02-15 2018-02-15 Methods
ARP190100349A AR114105A1 (es) 2018-02-15 2019-02-13 Inhibidor de gremlin-1 para el tratamiento de una fractura ósea o defecto óseo
EP19706471.0A EP3752527A1 (en) 2018-02-15 2019-02-14 Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect
BR112020015961-1A BR112020015961A2 (pt) 2018-02-15 2019-02-14 Inibidor de gremlin-1 para o tratamento de uma fratura óssea ou defeito ósseo
KR1020207026431A KR20200121833A (ko) 2018-02-15 2019-02-14 골절 또는 골결손의 치료를 위한 그렘린-1 억제제
US16/970,391 US11524997B2 (en) 2018-02-15 2019-02-14 Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect
JP2020542852A JP7395485B2 (ja) 2018-02-15 2019-02-14 骨折又は骨欠損の処置のためのグレムリン－１阻害剤
EA202091891A EA202091891A1 (ru) 2018-02-15 2019-02-14 Ингибитор гремлина-1 для лечения перелома кости или дефекта кости
PCT/EP2019/053726 WO2019158658A1 (en) 2018-02-15 2019-02-14 Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect
AU2019220407A AU2019220407B2 (en) 2018-02-15 2019-02-14 Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect
CA3090404A CA3090404A1 (en) 2018-02-15 2019-02-14 Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect
RU2020129443A RU2790992C2 (ru) 2018-02-15 2019-02-14 Ингибитор гремлина-1 для лечения перелома кости или дефекта кости
CN201980012164.7A CN111683965B (zh) 2018-02-15 2019-02-14 用于治疗骨折或骨缺损的gremlin-1抑制剂
MX2020007431A MX2020007431A (es) 2018-02-15 2019-02-14 Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto oseo.
SG11202005735SA SG11202005735SA (en) 2018-02-15 2019-02-14 Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect
IL276491A IL276491A (en) 2018-02-15 2020-08-04 Gremlin-1 inhibitor for the treatment of bone fracture or bone defect
CL2020002040A CL2020002040A1 (es) 2018-02-15 2020-08-05 Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos.
CONC2020/0009731A CO2020009731A2 (es) 2018-02-15 2020-08-06 Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos
CL2021002176A CL2021002176A1 (es) 2018-02-15 2021-08-17 Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos (divisional de la solicitud n° 202002040)
US18/062,608 US12240896B2 (en) 2018-02-15 2022-12-07 Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1802486.9A GB201802486D0 (en) 2018-02-15 2018-02-15 Methods

Publications (1)

Publication Number Publication Date
GB201802486D0 true GB201802486D0 (en) 2018-04-04

Family

ID=61783877

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1802486.9A Ceased GB201802486D0 (en) 2018-02-15 2018-02-15 Methods

Country Status (17)

Country Link
US (2) US11524997B2 (https=)
EP (1) EP3752527A1 (https=)
JP (1) JP7395485B2 (https=)
KR (1) KR20200121833A (https=)
CN (1) CN111683965B (https=)
AR (1) AR114105A1 (https=)
AU (1) AU2019220407B2 (https=)
BR (1) BR112020015961A2 (https=)
CA (1) CA3090404A1 (https=)
CL (2) CL2020002040A1 (https=)
CO (1) CO2020009731A2 (https=)
EA (1) EA202091891A1 (https=)
GB (1) GB201802486D0 (https=)
IL (1) IL276491A (https=)
MX (1) MX2020007431A (https=)
SG (1) SG11202005735SA (https=)
WO (1) WO2019158658A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
PL3806898T3 (pl) 2018-06-18 2026-02-23 UCB Biopharma SRL Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
CA3192306A1 (en) 2020-10-20 2022-04-28 Burkhard Ludewig Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
EP4511395A1 (en) 2022-04-20 2025-02-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
WO2024244941A1 (en) * 2023-05-26 2024-12-05 The University Of Hong Kong Compositions and methods for the treatment of bone loss
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1053002A1 (en) 1998-02-10 2000-11-22 Oregon Health Sciences University Treatment of bony defects with osteoblast precursor cells
AU2002243495A1 (en) 2001-01-12 2002-07-24 University Of Medicine And Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20120202710A1 (en) 2003-09-09 2012-08-09 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
EP1571159A1 (en) * 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
JP6339063B2 (ja) 2012-03-15 2018-06-06 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
ES2898620T3 (es) 2013-03-14 2022-03-08 Regeneron Pharma Anticuerpos humanos contra GREM 1
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
PL3806898T3 (pl) 2018-06-18 2026-02-23 UCB Biopharma SRL Antagonista gremlin-1 do zastosowania w leczeniu nowotworu

Also Published As

Publication number Publication date
MX2020007431A (es) 2020-09-14
AU2019220407A1 (en) 2020-08-27
JP7395485B2 (ja) 2023-12-11
IL276491A (en) 2020-09-30
EP3752527A1 (en) 2020-12-23
CO2020009731A2 (es) 2020-08-21
BR112020015961A2 (pt) 2020-12-15
CA3090404A1 (en) 2019-08-22
CN111683965B (zh) 2025-02-25
AU2019220407B2 (en) 2025-07-31
JP2021513960A (ja) 2021-06-03
US20230174635A1 (en) 2023-06-08
US20210107973A1 (en) 2021-04-15
US12240896B2 (en) 2025-03-04
EA202091891A1 (ru) 2020-10-29
RU2020129443A (ru) 2022-03-15
US11524997B2 (en) 2022-12-13
CN111683965A (zh) 2020-09-18
SG11202005735SA (en) 2020-07-29
KR20200121833A (ko) 2020-10-26
WO2019158658A1 (en) 2019-08-22
CL2020002040A1 (es) 2020-12-18
CL2021002176A1 (es) 2022-04-22
AR114105A1 (es) 2020-07-22

Similar Documents

Publication Publication Date Title
DK3793565T3 (en) Mcl-1-inhibitorer
DK3467457T3 (en) Vibrationssensor
DK3759096T3 (en) Cd73-inhibitorer
CA185383S (en) Casque
CA185382S (en) Casque
CA185384S (en) Casque
CA185385S (en) Casque
DK3872428T3 (en) Indvendigt luftstyringssystem
DK3773537T3 (en) Stat3-hæmmere
DK3554057T3 (en) Audioheadsetsystem
DK3768830T3 (en) Cancerterapi
CA184994S (en) Uroflowmeter
DK3613739T3 (en) Integrin-antagonister
GB201803724D0 (en) Methods
GB201802486D0 (en) Methods
DK3753395T3 (en) Indvendigt luftstyringssystem
CA184989S (en) Uroflowmeter
GB201805466D0 (en) Methods
DK3633783T3 (en) Universal-powerbank
EP3841303C0 (de) Mikrogebläse
DK3801538T3 (en) Tlr7-agonister
SG11202007342QA (en) Methods
DK3768906T3 (en) Træmodul
DK3650069T3 (en) Trakeostomiventil
GB201814451D0 (en) Methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)